NCT06414317Active, not recruiting
An Education and Navigation Support Tool to Improve Participation in Care Coordination Among Patients With Locally Advanced, Metastatic and Unresectable Bladder Cancer and Their Caregivers
A Comprehensive Education and Navigational Support Program for Advanced Bladder Cancer
Source: ClinicalTrials.gov · Last updated 5 Nov 2026
Brief summary (registry, in English)
This clinical trial evaluates the impact of an education and navigation support tool (ENST) on patient and caregiver participation in care coordination for bladder cancer that has spread to nearby tissue or lymph nodes (locally advanced), to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Patients with advanced bladder cancer tend to be older, have multiple medical conditions and often have poor access to health care. An ENST may be an effective method to improve participation in treatment decision-making and care planning among patients with locally advanced, metastatic and unresectable bladder cancer and their caregivers.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 12 (actual)
- First submitted
- 6 May 2024
- Start date
- 12 Jan 2024
- Primary completion date
- 25 Sept 2026
- Lead sponsor
- Roswell Park Cancer Institute
- Diseases
- Bladder cancer
- NCT number
- NCT06414317
What you commit to
- Study type: Interventional
- Participants enrolled: 12
- From 12 Jan 2024 to the primary completion date, 25 Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- PATIENTS: Not receiving any form of systemic therapy for bladder cancer due to Eastern Cooperative Oncology Group (ECOG) performance status (PS) \> 3, co-morbidities, or inadequate organ function
Other
- PATIENTS: Predominantly small cell histology
- PATIENTS: Adults with impaired decision-making capacity, assessed by the study team to be unable to participate in ENST-based education and surveys
- PATIENTS: Pregnant women
- CAREGIVERS: Cognitively impaired adults/adults with impaired decision-making capacity
- CAREGIVERS: Individuals who are not yet adults (infants, children, teenagers)
Who the study is looking for
- PATIENTS: Age ≥ 18 years
- PATIENTS: Metastatic or locally advanced, unresectable bladder cancer
- PATIENTS: Receiving or planning to receive systemic therapy for bladder cancer at Roswell Park Comprehensive Cancer Center (RPCCC)
- PATIENTS: Subjects can be enrolled any time from initial diagnosis of advanced disease to within 8 weeks after initiation of first-line systemic therapy for advanced bladder cancer
- PATIENTS: Able to speak, understand, read, and write English
- CAREGIVERS: Age ≥ 18 years
- CAREGIVERS: Only caregivers of enrolled patients will be included in the study
- CAREGIVERS: Should be able to speak, understand, read, and write English
- CAREGIVERS: Caregivers will be enrolled in the study during the same time window as for patient enrollment (from initial visit to within 8 weeks of patients starting frontline therapy)
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Roswell Park Cancer Institute Coordinator of this site? Confirm its status | Buffalo | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.